Literature DB >> 31919629

Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy.

Mariko Okubo1,2, Satoru Noguchi3, Shinichiro Hayashi1, Harumasa Nakamura4, Hirofumi Komaki5, Masafumi Matsuo6, Ichizo Nishino1.   

Abstract

Duchenne muscular dystrophy (DMD) is caused by a nonsense or frameshift mutation in the DMD gene, while its milder form, Becker muscular dystrophy (BMD) is caused by an in-frame deletion/duplication or a missense mutation. Interestingly, however, some patients with a nonsense mutation exhibit BMD phenotype, which is mostly attributed to the skipping of the exon containing the nonsense mutation, resulting in in-frame deletion. This study aims to find BMD cases with nonsense/frameshift mutations in DMD and to investigate the exon skipping rate of those nonsense/frameshift mutations. We searched for BMD cases with nonsense/frameshift mutations in DMD in the Japanese Registry of Muscular Dystrophy. For each DMD mutation identified, we constructed minigene plasmids containing one exon with/without a mutation and its flanking intronic sequence. We then introduced them into HeLa cells and measured the skipping rate of transcripts of the minigene by RT-qPCR. We found 363 cases with a nonsense/frameshift mutation in DMD gene from a total of 1497 dystrophinopathy cases in the registry. Among them, 14 had BMD phenotype. Exon skipping rates were well correlated with presence or absence of dystrophin, suggesting that 5% exon skipping rate is critical for the presence of dystrophin in the sarcolemma, leading to milder phenotypes. Accurate quantification of the skipping rate is important in understanding the exact functions of the nonsense/frameshift mutations in DMD and for interpreting the phenotypes of the BMD patients.

Entities:  

Year:  2020        PMID: 31919629     DOI: 10.1007/s00439-019-02107-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  5 in total

1.  A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy.

Authors:  Salvo Danilo Lombardo; Maria Sofia Basile; Rosella Ciurleo; Alessia Bramanti; Antonio Arcidiacono; Katia Mangano; Placido Bramanti; Ferdinando Nicoletti; Paolo Fagone
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

2.  Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.

Authors:  Shu Zhang; Dongdong Qin; Liwen Wu; Man Li; Lifang Song; Cuijie Wei; Chunling Lu; Xiaoli Zhang; Siqi Hong; Mingming Ma; Shiwen Wu
Journal:  Orphanet J Rare Dis       Date:  2021-04-28       Impact factor: 4.123

3.  Dual Fluorescence Splicing Reporter Minigene Identifies an Antisense Oligonucleotide to Skip Exon v8 of the CD44 Gene.

Authors:  Sachiyo Fukushima; Manal Farea; Kazuhiro Maeta; Abdul Qawee Mahyoob Rani; Kazumichi Fujioka; Hisahide Nishio; Masafumi Matsuo
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

Review 4.  Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot.

Authors:  Harry Wilton-Clark; Toshifumi Yokota
Journal:  Genes (Basel)       Date:  2022-01-28       Impact factor: 4.096

5.  miR-31-5p-DMD axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer.

Authors:  Changqin Liu; Wei Wu; Wenju Chang; Ruijin Wu; Xiaomin Sun; Huili Wu; Zhanju Liu
Journal:  Oncol Lett       Date:  2022-03-17       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.